ADVANCEMENTS IN THE TREATMENT OF LIVER DISORDERS USING RESEALED ERYTHROCYTES

Abstract

Red Blood Cells (RBCs) have distinct qualities including biocompatibility, biodegradability and the ability to release drugs selectively are becoming a viable drug delivery platform these days. The reversible opening of erythrocyte membranes made feasible by recent developments in nanopore technology permits efficient loading and encapsulation of therapeutic drugs. This strategy has the potential to transform both therapeutic and diagnostic applications to be flexible and targeted drug administration. Since resealed erythrocytes can accurately deliver medications while minimizing side effects, they show great potential in both passive and active targeted applications. Erythrocytes also can flex through capillaries and their biconcave form improves their effectiveness as drug transporters. Numerous techniques have been developed for encapsulating pharmaceuticals with erythrocytes, such as electro-encapsulation, hypotonic dilution, and hypotonic haemolysis. Each of these approaches has unique benefits with controlled release and drug loading efficiency. The use of erythrocytes in drug delivery has significant advantages over other factors, such as potential alterations to erythrocyte physiology and the reticuloendothelial system (RES) rapid clearance. In addition, Resealed erythrocytes have demonstrated exceptional potential in delivering antineoplastic medicines, targeting hepatic tumours, and providing enhanced pharmacokinetics in treating liver problems. These carriers may become widely used in therapeutic settings, especially for the facilitated delivery of hormones, steroids, and biopharmaceuticals. The future prospects of erythrocyte-based drug delivery systems as an innovative and attainable strategy in modern medicine are highlighted in this paper.